Audrey Chen, OD
Optometrist · Palm Desert, CANPI 1750546156
Payments from drug & device makers
Across 30 payments — averaging $62.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$516
- Aerie Pharmaceuticals, Inc.$258
- Glaukos Corporation$202
- Nova Eye, Inc.$149
- Johnson & Johnson Vision Care, Inc.$145
- Astellas Pharma US Inc$129
- plus $477 from 6 others
What the payments were for
- Food & beverage$1,85699%
- Gifts$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 7 | $516 |
| Aerie Pharmaceuticals, Inc. | 7 | $258 |
| Glaukos Corporation | 2 | $202 |
| Nova Eye, Inc. | 1 | $149 |
| Johnson & Johnson Vision Care, Inc. | 1 | $145 |
| Astellas Pharma US Inc | 1 | $129 |
| Apellis Pharmaceuticals, Inc. | 1 | $125 |
| Alcon | 6 | $123 |
| Regeneron Healthcare Solutions, Inc. | 1 | $92 |
| Visioneering Technologies, Inc. | 1 | $59 |
| Astellas Pharma Global Development | 1 | $58 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$374
- XIIDRA$249
- Rocklatan$238
- Rhopressa$238
- Acuvue$145
- KXL System$144
- Photrexa Viscous and Photrexa$144
- Syfovre$125
- INFUSE$122
How this compares
$1,876 in reported general payments places this provider in the 75th percentile of 6,778 optometrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Timolol Maleate | 22 | $1,298 |
| Latanoprost | 53 | $791 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 17 | $544 |
| Brimonidine Tartrate | 12 | $539 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Palm Desert
- Meng LinBerkeley$6.9M
- Steve YoelinNewport Beach$6.1M
- Matthew GellerSpring Valley$3.5M
- David Kasanoffla Mesa$1M
- Colton HeinrichFullerton$987K
- Elsa PaoOakland$910K
- Keith WanSan Diego$887K
- Selena ChanSan Francisco$677K
- Melissa EricksonDavis$522K
- Omid KhodaiLake Forest$499K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.